COMPASS Pathways
Location: London, UK
Hours: Clinical trial sites vary
About COMPASS Pathways
COMPASS Pathways is a UK-based biopharmaceutical company developing COMP360 — a synthetic, standardized psilocybin — for treatment-resistant depression. Having completed a significant Phase 2b trial showing dose-dependent effects, COMPASS is advancing toward Phase 3 clinical trials. It represents the largest corporate investment in psilocybin therapy development globally and is the leading candidate for eventual FDA approval of a psilocybin-based treatment.
Location & Legal Context
COMPASS Pathways operates in United Kingdom. Before visiting or purchasing, review the psilocybin laws in United Kingdom to understand the current legal landscape.
How We Classify This Listing
Directory listings are informational, not endorsements. For regulated psilocybin services, verify licensing with the relevant state program before booking or paying.
Community Reviews
Community reviews coming in Phase 2. Have you worked with COMPASS Pathways? Share your experience in the forum.